Charts NXS, page-510

From the last 4C " As we commercialise our technologies, the revenue growth trajectory will continue to be lumpy in coming quarters as initial orders from our distribution partners tend to be large and irregular". The aquisition of KCI has impacted the sales of their wound care product in the short term, but has now given them access to more patients. When buying into companies in their infancy this is common as take up of the product ramps up to base sales.

Management have been honest and disclosed this so in the short term I believe this is an opportunity to take an initial position or top up current holdings. They have a good product, plenty of cash and the story is still intact.

Catalyst for price appreciation will be CE approval and 4 new product launches in 2020.